Advertisement
IDYA vs RNA
Which Stock Would AI Choose? IDEAYA Biosciences (IDYA) vs. Atrium Therapeutics (RNA) Stock Comparison
Key Takeaways
- IDYA is a clinical-stage precision oncology company with a lead asset nearing potential regulatory submission, while RNA is now Atrium Therapeutics, a preclinical cardiology biotech spun out of Avidity Biosciences.
- IDYA carries a Strong Buy analyst consensus and a large cash position, but remains deeply loss-making and recently pulled back from highs.
- RNA is a newly independent, early-stage company with a much smaller float and substantially higher volatility, including a steep decline in recent weeks.
- The two names differ sharply in maturity: IDYA is pursuing near-term commercial catalysts, whereas RNA's value rests on preclinical programs years from the market.
- Relative performance and risk profiles are driven less by shared sector exposure than by pipeline stage and corporate structure.
Introduction
Investors evaluating biotechnology often weigh companies at very different points along the drug-development lifecycle. This stock comparison puts two RNA and precision-medicine developers side by side: IDYA, a precision oncology specialist, and RNA, the ticker now held by Atrium Therapeutics following the acquisition of Avidity Biosciences. The contrast is instructive for growth-oriented traders and longer-horizon biotech investors alike, because it highlights how relative performance and market positioning can diverge between a late-stage, catalyst-rich name and a freshly listed preclinical company. Understanding each company's business model, momentum, and risk factors helps clarify where the balance of opportunity and uncertainty currently sits.
IDYA Overview and Recent Performance
IDYA, or IDEAYA Biosciences, is a precision medicine oncology company developing targeted therapies for patient populations selected through molecular diagnostics. Its pipeline is anchored by darovasertib for metastatic uveal melanoma, where the company has been advancing an NDA (New Drug Application) submission with Fast Track designation, alongside earlier-stage assets such as IDE849 targeting DLL3 in small cell lung cancer and IDE892, a PRMT5 inhibitor for MTAP-deleted solid tumors.
In recent market activity, IDEAYA has experienced a choppy phase, pulling back from levels reached earlier in the year even as its longer-term trajectory remains positive. The company reported modest revenue against widening net losses in its latest quarter, consistent with a business still investing heavily in research and development (R&D). A leadership change concentrated R&D responsibility in a single executive, and the company announced a clinical collaboration with Roche. Analysts have largely maintained Buy ratings, with a consensus price target above recent trading levels, reflecting conviction in the pipeline despite near-term execution risk. A cash balance of roughly $1.2 billion provides an extended runway.
RNA Overview and Recent Performance
RNA is now the ticker for Atrium Therapeutics, a biotechnology company formed through the spin-off of Avidity Biosciences' early-stage precision cardiology programs. The change followed the completion of Novartis' roughly $12 billion acquisition of Avidity in early 2026, with Atrium inheriting the Nasdaq symbol. The company is developing RNA-based therapies, specifically small interfering RNA (siRNA) approaches, for rare genetic cardiomyopathies.
Atrium's pipeline is entirely preclinical, led by ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. It launched with approximately $270 million in cash and has since completed a private placement financing, underscoring ongoing capital needs. In recent weeks, the stock has shown pronounced volatility and a meaningful decline, reflecting both the typical selling pressure that follows a spin-off and the inherent uncertainty of preclinical-stage assets. Atrium holds collaboration agreements with Bristol Myers Squibb and Eli Lilly, and its first IND (Investigational New Drug) filing is anticipated in the near term, marking an early milestone investors are watching.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots, selected for their suitability to current market conditions. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance metrics, and basket of securities. Because no single approach fits every market environment, only the best-performing and most appropriate robots earn a place in this featured section. For traders comparing names such as IDYA and RNA, reviewing how AI models rank trend consistency, volatility, and relative momentum can add a data-driven layer to their analysis. Explore the Trending AI Robots section to see which strategies are currently favored.
Head-to-Head Comparison
The most fundamental contrast between IDYA and RNA is pipeline maturity. IDEAYA is positioned closer to potential commercialization, with a lead candidate in registrational-stage development and multiple clinical programs, whereas Atrium's entire pipeline remains preclinical. This gap directly shapes each company's risk profile and market positioning.
Growth drivers also differ. IDYA's near-term catalysts center on regulatory filings and clinical readouts across oncology, supported by a broad balance sheet and strong sell-side support. RNA's drivers are earlier-stage: IND filings, initial human data, and partnership economics in a niche cardiology field. Recent momentum has been mixed for both, but the scale of volatility is not comparable—Atrium's small float and recent financing have amplified price swings, while IDEAYA's pullback has been more moderate against a longer positive trend.
On sector exposure, both are biotechnology, yet their sub-sectors—oncology versus rare cardiac disease—carry different competitive and regulatory dynamics. Sentiment toward IDYA leans constructive on pipeline breadth and capital strength, while sentiment toward RNA reflects the uncertainty of a newly independent, pre-revenue entity. These contrasts make the two names more complements than direct competitors in a diversified biotech view.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely favor IDYA over RNA in the current environment. IDEAYA combines a more advanced pipeline, a stronger analyst consensus, and a substantially larger cash runway, which tends to support more stable relative performance despite ongoing losses. Atrium, by contrast, carries higher volatility and earlier-stage execution risk, which can make its trend signal less reliable for momentum-oriented models. This is a probabilistic assessment rather than a definitive prediction: both stocks remain subject to clinical, regulatory, and financing risks, and AI-driven rankings can shift as new data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and RNA is a Hold.
IDYA's RSI Oscillator ascends from oversold territory
The RSI Indicator for IDYA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 63 cases where IDYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on November 11, 2026. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 217 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 81 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.514) is normal, around the industry mean (3.498). P/E Ratio (-16.271) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RNA's RSI Oscillator ascending out of oversold territory
The RSI Indicator for RNA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 28 of the 33 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 61 cases where RNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNA as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.665) is normal, around the industry mean (3.498). P/E Ratio (-1.533) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IDYA | RNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 80 | 100 | |
SMR RATING 1..100 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 60 | 80 | |
P/E GROWTH RATING 1..100 | 30 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDYA's Valuation (11) in the null industry is in the same range as RNA (36). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's Profit vs Risk Rating (80) in the null industry is in the same range as RNA (100). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's SMR Rating (94) in the null industry is in the same range as RNA (97). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
IDYA's Price Growth Rating (60) in the null industry is in the same range as RNA (80). This means that IDYA’s stock grew similarly to RNA’s over the last 12 months.
RNA's P/E Growth Rating (15) in the null industry is in the same range as IDYA (30). This means that RNA’s stock grew similarly to IDYA’s over the last 12 months.
| IDYA | RNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 83% | 7 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| Advances ODDS (%) | 4 days ago 75% | 4 days ago 77% |
| Declines ODDS (%) | 10 days ago 76% | 2 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 81% | N/A |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDYA’s FA Score shows that 2 FA rating(s) are green while RNA’s FA Score has 1 green FA rating(s).
- IDYA’s FA Score: 2 green, 3 red.
- RNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDYA’s TA Score shows that 5 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).
- IDYA’s TA Score: 5 bullish, 3 bearish.
- RNA’s TA Score: 3 bullish, 4 bearish.
Price Growth
IDYA (@Biotechnology) experienced а +1.10% price change this week, while RNA (@Biotechnology) price change was -8.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.18%. For the same industry, the average monthly price growth was -2.37%, and the average quarterly price growth was -16.49%.
Reported Earning Dates
IDYA is expected to report earnings on Feb 23, 2027.
RNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+7.18% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IDYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with RNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To IDYA | 1D Price Change % | ||
|---|---|---|---|---|
| IDYA | 100% | +3.04% | ||
| RNA - IDYA | 48% Loosely correlated | -3.28% | ||
| SLDB - IDYA | 47% Loosely correlated | +6.00% | ||
| EDIT - IDYA | 45% Loosely correlated | -4.99% | ||
| DYN - IDYA | 44% Loosely correlated | +0.39% | ||
| MGTX - IDYA | 44% Loosely correlated | +0.62% | ||
More | ||||
RNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To RNA | 1D Price Change % | ||
|---|---|---|---|---|
| RNA | 100% | -3.28% | ||
| DYN - RNA | 64% Loosely correlated | +0.39% | ||
| PBYI - RNA | 49% Loosely correlated | -0.74% | ||
| DSGN - RNA | 48% Loosely correlated | +1.13% | ||
| IDYA - RNA | 48% Loosely correlated | +3.04% | ||
| NTLA - RNA | 42% Loosely correlated | +2.15% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AGEM | 45.55 | 1.17 | +2.63% |
| abrdn Emerging Markets Dividend Active ETF (AGEM) | |||
| LDRH | 23.96 | 0.01 | +0.04% |
| iShares iBonds 1-5 Year High Yield and Income Ladder ETF | |||
| QQQX | 30.68 | N/A | N/A |
| Nuveen NASDAQ 100 Dynamic Overwrite Fund | |||
| FLSW | 44.69 | -0.36 | -0.80% |
| Franklin FTSE Switzerland ETF (FLSW) | |||
| CGRO | 16.35 | -0.27 | -1.61% |
| CoreValues Alpha Greater China Growth ETF (CGRO) | |||